This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma
Patients fully understand the study, voluntarily participate in and sign on the informed consent;
Diagnosed by histopathology Peripheral T-cell lymphoma;
ECOG PS score 0 or 1;
Relapsed or Refractory Peripheral T Cell Lymphoma；
NK/T-cell lymphoma;
Achieving CR or PR after induction chemotherapies without relapse;
Dysfunction of vital organs;
Serious history of autoimmune diseases and immunodeficiency, including: positive for human immunodeficiency virus (HIV) antibodies; Or other acquired or congenital immunodeficiency diseases; Or have a history of organ transplantation;
Single group
Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Other interventionDrug: Pralatrexate, Chidamide 1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment) 2. After the 6-week therapy, the patients should receive PET/CT evaluation. 3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week. 4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies.
Progression-free survival (PFS) at 1 year after transplantation
The time from the end of transplantation to progression of disease or death at 1year
Click on the lead sponsor to view all of their trials.
Peking University People's Hospital
Lead sponsor
Ruijin Hospital
Collaborator
Wuhan TongJi Hospital
Collaborator
West China Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
